Basic Information
GBT is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies to bring hope to underserved patient populations. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily treatment for sickle cell disease.
Global Blood Therapeutics, Inc.
SanFrancisco,California,United States of America
101~500 people
January 01, 2012
info@gbt.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios